Zacharos I D, Efstathiou S P, Petreli E, et al. The prognostic significance of CA125 in patients with non- Hodgkin's lymphoma [J]. Eur J Haematol, 2002, 69(10): 221- 226.
Zidan J,Hussein O,Basher W, et al. Serum CA125:A tumor marker for monitoring Response to Treatment and Follow-up in patients with Non-Hodgkin’s lymphoma[J]. The oncologist ,2004,9(4):417-421.
[6]
Russo F, Lastoria S, Svanera G, et al. Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma[J]. Leuk Lymphoma, 2007,48(4):723-730.
[7]
Dilek I, Ayakta H, Demir C ,et al.CA125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies [J].Clin Lab Haematol,2005, 27(1):51-55.
[8]
Zacharos I D, Efstathiou S P, Petreli E, et al. The prognostic significance of CA125 in patients with non- Hodgkin's lymphoma [J]. Eur J Haematol, 2002, 69(10): 221- 226.
Gubbels JA1, Felder M, Horibata S ,et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells [J]. Mol Cancer, 2010,9(11):11-13.